Asset Details
Do you wish to reserve the book?
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Do you wish to request the book?
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022
Overview
Purpose
Despite advances in adjuvant therapeutic strategies, many patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) experience disease recurrence, even many years after primary surgery. The aim of this review is: (i) to point out the current clinical, pathological, and genomic features that contribute to define the risk of recurrence in HR-positive EBC, (ii) to explore the potential role of liquid biopsy-based assays for refining risk assessment, and (iii) to discuss future perspectives and innovative strategies to optimize risk stratification and select patients for treatment escalation.
Methods
We searched PubMed, EMBASE and Scopus to review the current evidence about risk stratification in patients with HR-positive EBC, and to identify studies deemed to have the highest scientific value.
Results
Risk stratification of HR-positive/HER2-negative relies on traditional clinicopathological features (age, menopausal status, tumor size, nodal status, tumor grading, HR expression level, and proliferation markers), along with newly developed genomic scores, which accurately predict risk of recurrence and survival. Multiparametric scores including both clinicopathological and genomic variables have the highest prognostication power, even if comparative studies have not defined which one should be preferred. In parallel, liquid biopsy-based showed to be a valuable tool to identify high risk patients.
Conclusion
The most appropriate definition of “high” and “low” risk HR-positive EBC is still unclear. Accordingly, treatment escalation/de-escalation depending on recurrence risk remains challenging. Implementation of new tools for risk stratification, such as liquid biopsy-based assays, as well as development of novel treatment strategies are strongly warranted.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Biopsy
/ Breast Neoplasms - diagnosis
/ Diseases
/ Female
/ Genomics
/ Humans
/ Medicine
/ Neoplasm Recurrence, Local - drug therapy
/ Oncology
/ Patients
/ Receptor, ErbB-2 - metabolism
/ Relapse
/ Review
/ Tumors
We currently cannot retrieve any items related to this title. Kindly check back at a later time.